- Conditions
- Central Auditory Processing Disorder, Hearing Impaired (Partially), Hearing, Hearing Abnormality, Hearing Disability, Hearing Disorder, Hearing Disorders, Hearing Impairment, Sensorineural, Hearing Handicap, Hearing Impaired, Hearing Impairment, Hearing Loss, Central Auditory Disease, Noise Exposure, Noise Induced Hearing Loss, Noise-Induced Hearing Loss, Sound Perception, Myelin Degeneration, Myelinopathy, Myelin Integrity, Remyelination, Hidden Hearing Loss, Cocktail Party Skill, Cocktail Party Syndrome, CAPD, Age Problem
- Interventions
- Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound, Placebo - Placebo
- Combination Product · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis
- Interventions
- Natalizumab 300 MG in 15 ML Injection
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee